Xenon Pharmaceuticals (Nasdaq: XENE) will announce topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures on Monday, March 9, 2026. A live webcast and replay will be available via the company's Investors website; conference call details are provided.
Conference call: 8:00 am ET (5:00 am PT) on March 9, 2026; dial-in and webcast registration information available.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
This announcement confirms the date and time for topline results from the Phase 3 X-TOLE2 study of a...
Analysis
This announcement confirms the date and time for topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures on March 9, 2026, along with webcast logistics. It follows prior disclosures outlining March timing and a broader Phase 3 program in epilepsy and mood disorders. Investors may focus on how these results integrate with existing long-term seizure-reduction data and the company’s stated plans for potential regulatory submissions.
Key Figures
Topline results date:March 9, 2026Conference call time ET:8:00 am ETConference call time PT:5:00 am PT+3 more
48‑month OLE data showing sustained seizure reductions and safety.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows several instances where positive clinical and corporate updates were followed by negative price reactions, indicating a tendency for sell-offs around seemingly favorable news.
Recent Company History
Over recent months, Xenon has highlighted late-stage progress for azetukalner, including expectations for X-TOLE2 topline data in March 2026 and a potential NDA submission in H2 2026. Presentations at the 2026 J.P. Morgan Healthcare Conference reiterated multiple Phase 3 programs and Phase 1 pain candidates. Long-term 48‑month OLE data showed durable seizure reductions and periods of seizure freedom. The upcoming X-TOLE2 topline fits directly into this sequence of advancing azetukalner’s epilepsy program toward potential regulatory filings.
Key Terms
phase 3, focal onset seizures, kv7 potassium channel opener, major depressive disorder, +2 more
6 terms
phase 3medical
"topline data from the Phase 3 X-TOLE2 study of azetukalner"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
focal onset seizuresmedical
"in patients with focal onset seizures (FOS), on Monday, March 9, 2026."
Focal onset seizures are seizures that begin in a specific part of the brain and can cause localized symptoms such as brief changes in awareness, unusual sensations, or jerking in one limb; they can sometimes spread to affect the whole brain. Investors care because these seizures define patient groups, influence how drugs and devices are tested and approved, and shape market size, pricing and risk — like a localized outage that requires a targeted fix rather than a whole-system replacement.
kv7 potassium channel openermedical
"azetukalner, a novel, potent KV7 potassium channel opener, in patients"
A Kv7 potassium channel opener is a drug that helps certain cellular ‘gates’ called Kv7 channels stay open so potassium can flow out of cells, calming electrical activity in nerves and muscle. For investors, these compounds matter because they can form the basis of treatments for conditions driven by excessive electrical firing—like some seizures, pain, or heart rhythm disorders—so successful candidates can create new medical markets or reduce risks in drug pipelines.
major depressive disordermedical
"clinical trials for the treatment of epilepsy, major depressive disorder (MDD)"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
bipolar depressionmedical
"epilepsy, major depressive disorder (MDD) and bipolar depression (BPD)."
Bipolar depression is the low-mood phase of bipolar disorder, when a person experiences prolonged sadness, low energy, slowed thinking, and loss of interest in daily activities; think of it as the downward swing in a mood pendulum. It matters to investors because it shapes demand for treatments, the design and outcome of clinical trials, regulatory approval chances, and long-term healthcare costs—factors that affect the commercial potential of therapies and medical companies.
nav1.7medical
"including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment"
NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.
(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:
7885306
A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
For Media: Colleen Alabiso Senior Vice President, Corporate Affairs media@xenon-pharma.com
FAQ
When will Xenon (XENE) announce Phase 3 X-TOLE2 topline results?
Xenon will announce topline X-TOLE2 results on Monday, March 9, 2026. According to the company, the announcement will be made via a live webcast and conference call starting at 8:00 am ET with replay posted afterwards.
How can investors listen to Xenon (XENE) topline results on March 9, 2026?
Investors can join a live webcast or dial into the conference call at the scheduled time. According to the company, webcast registration is available on Xenon's Investors website and dial-in numbers are provided for both domestic and international callers.
What is being reported in the X-TOLE2 study announcement for XENE?
The announcement will deliver topline data from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures. According to the company, azetukalner is a novel KV7 potassium channel opener currently in Phase 3 development for epilepsy.
What time is Xenon's (XENE) conference call and what are the dial-in details?
The conference call is scheduled for 8:00 am ET (5:00 am PT) on March 9, 2026 with Conference ID 7885306. According to the company, toll-free and international dial-in numbers are provided alongside webcast access for listeners.
Which indications is azetukalner being developed for besides focal onset seizures?
Azetukalner is also in development for major depressive disorder and bipolar depression. According to the company, azetukalner is being evaluated across multiple CNS indications including Phase 3 for epilepsy and other mood disorder programs.
